華潤醫藥(03320.HK)附屬華潤醫藥商業獲增資46.5億人幣
華潤醫藥(03320.HK)公布,華潤醫藥商業註冊資本由150億元人民幣(下同),增加46.47億元至196.47億元。當中,投資者認購人增資共39.04億元,代價總額為52.6億元;公司的全資附屬北京醫藥及華潤醫藥投資(現有股東認購人)增資共7.42億元,代價總額為10億元。
華潤醫藥商業由北京醫藥及華潤醫藥投資擁有約88.67%及約11.33%,且入賬列作公司的全資附屬。華潤醫藥商業乃主要從事醫藥商品營銷、物流配送以及提供醫藥供應鍵解決方案服務,是次增加的註冊資本擬用於其主營業務經營,直接或間接用於償還華潤醫藥商業及其附屬公司現有銀行貸款。
完成後,華潤醫藥商業將由北京醫藥、華潤醫藥投資分別擁有約71.05%及約9.08%權益。因此,公司於華潤醫藥商業的權益將因建議增加註冊資本及建議認購事項而由100%攤薄至約80.13%。
投資者認購人包括建信金融資產投資、農銀金融資產投資、工銀金融資產投資、交銀金融資產投資、中銀金融資產投資、北京國瑞中鑫及北京人保健康養老產業投資基金。
公司認為,建議增加註冊資本為有效應對醫藥產業變革的挑戰,提高華潤醫藥商業國有資本配置和運行效率,補足融資創新能力短板,建立差異化細分業態競爭優勢。同時,通過建議認購事項引入外部投資者有利於優化華潤醫藥商業資本結構,擴大業務規模,完善公司治理,推動業績增長,也將為公司帶來積極貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.